Skip to main content

Table 1 Characteristics of included studies in the meta-analysis (MSCs group)

From: Mesenchymal stromal cells as prophylaxis for graft-versus-host disease in haplo-identical hematopoietic stem cell transplantation recipients with severe aplastic anemia?—a systematic review and meta-analysis

Author, reference (publication year) Study design Recruitment period Number of patients Median age Sex (M/F) Type Conditioning regimen GVHD prophylaxis Interval from diagnosis to treatment (M) Neutrophil recovery (d) Platelet engraftment MSCs originals NOS score
Wang Z-K [31] (2019) Single-arm study January 2014-December 2016 35 11.5 (3–18) 18/17 SAA/VSAA (19/16) Busulfan (Bu) + cyclophosphamide (Cy) + antithymocyte globulin (ATG) CsA + MMF + MTX NA 14 (10–22) 18 (9–36) BM 6
Yue C [32] (2018) Cases January 2014-January 2017  6 23 (15–31) 3/3 VSAA (6) Busulfan (Bu) + cyclophosphamide (Cy) + antithymocyte globulin (rATG) CsA + MMF + MTX 2 (1–3.5) 13 (9–19) 15.5 (10–23) BM 5
Liu Z [33] (2017) Single-arm study March 2013-August 2015 44 24 (8–47) 29/15 SAA/VSAA (31/13) Busulfan (Bu) + cyclophosphamide (Cy) + antithymocyte globulin (ATG) CsA + MMF + MTX 31.2 (1–249) 12 (8–21) 19 (8–154) BM 6
Xu L [34] (2018) Single-arm study June 2010-August 2013 24 16.5 (5–55) 14/10 SAA (24) Cyclophosphamide (Cy) + antithymocyte globulin (rATG) + FLU or CsA + ATG+ CD25Ab + mycophenolate material NA 11 (10–25) 13 (10–25) UC 6
Wu Y [35] (2017) Single-arm study January 2011-June 2016 77 9 (1–46) 39/38 SAAVSAA/SAA and PNH (72/5) Cyclophosphamide (Cy) + antithymocyte globulin (ATG) + FLU ± busulfan CsA + MMF + MTX + CD25Ab 7 (2–182) 12(8–21) 14 (9–30) UC 5
Li XH [36] (2014) Single-arm study October 2006-October 2012 17 19 (4–29) 10/7 SAA/VSAA (8/9) Cyclophosphamide (Cy) + antithymocyte globulin (ATG) + FLU CsA + MMF + CD25Ab 3 (1–5) 12 (11–21) 14 (11–75) UC 6
Wu Y [37] (2014) Single-arm study January 2007-June 2013 21 18 (4–31) 11/10 SAA/VSAA/SAA and PNH (7/12/2) Cyclophosphamide (Cy) + antithymocyte globulin (rATG) + FLU or CsA + MMF + CD25Ab + rATG 6 (1–128) 12 (8–21) 14(10–23) UC 6
Wang Z [38] (2014) Single-arm study March 2010-April 2013 17 10 (4–19) 6/11 SAA/VSAA/2 HSCT (11/5/1) BU + fludarabine + CY + ATG CsA + MMF + MTX + CD25Ab 12 (1–44) 16 (9–25) 22 (9–95) UC 6
  1. Abbreviations: SAA severe aplastic anemia, VSAA very severe aplastic anemia, ATG antithymoglobulin, CsA cyclosporin A, MSCs mesenchymal stem cells, haplo-HSCT haplo-identical hematopoietic stem cell transplantation, BU busulfan, Cy cyclophosphamide, MMF mycophenolate mofetil, FLU fludarabine, MTX methotrexate, GVHD graft-versus-host disease